Cover Image
Read Now

Omalizumab (Xolair) treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria

The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2015, 2015
Series:Common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01114nam a2200217 u 4500
001 EB002220284
003 EBX01000000000000001357245
005 00000000000000.0
007 tu|||||||||||||||||||||
008 240703 r ||| eng
245 0 0 |a Omalizumab (Xolair)  |h Elektronische Ressource  |b treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2015, 2015 
300 |a 1 PDF file  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK362676  |3 Volltext 
082 0 |a 610 
520 |a The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment 

Similar Items